At VB Transform 2026, Stanford’s James Zou introduced a revolutionary approach to AI where tens of thousands of specialized AI agents collaborate rather than relying on a single model. His team created a “Virtual Biotech” system that mimics a corporate biotech structure, complete with divisions for target discovery, molecule design, and clinical trials, overseen by a Chief Scientific Officer agent. This multi-agent setup outperformed single-agent models by encouraging debate and rigorous reasoning among agents, resulting in superior scientific outcomes.
The team developed Paperclip, an AI-native system that integrates unstructured data into a unified virtual file system for easy agent access, vastly improving accuracy and efficiency. Virtual Biotech launched 37,000 agents to analyze clinical trial data, identifying predictive single-cell features that increased drug success rates.
Remarkably, these agents autonomously designed an antibody-drug conjugate for lung cancer targeting the CD276 protein, using only pre-2025 data. Merck later independently created and validated the same design, gaining FDA breakthrough designation, confirming the AI system’s real-world effectiveness.
Zou emphasized shifting from fixed workflows to open environments that foster agent collaboration, optimizing the ecosystem rather than individual models. This innovative orchestration paves the way for scalable, robust AI-driven biotech research.
